What is Virios Therapeutics' operating income?

Virios Therapeutics' total operating income in 2025 was -$27.97 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $27.97 million

Virios Therapeutics (VIRI) Financials

$1.44 +0.01 (+0.70%)

As of 07/15/2026

Compare

Annual Income Statements for Virios Therapeutics

This table shows Virios Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-10	-16	-12	-5.30	-13	-36
Consolidated Net Income / (Loss)	-10	-16	-12	-5.30	-12	-34
Net Income / (Loss) Continuing Operations	-10	-16	-12	-5.30	-12	-34
Total Pre-Tax Income	-10	-16	-12	-5.30	-12	-34
Total Operating Income	-10	-16	-12	-5.45	-12	-28
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	10	16	12	5.45	12	28
Selling, General & Admin Expense	9.81	4.85	4.25	3.72	8.70	6.10
Research & Development Expense	0.19	11	8.07	1.73	3.53	22
Other Special Charges / (Income)	-	-	-	-	0.00	0.00
Total Other Income / (Expense), net	-0.34	-0.31	0.13	0.15	-0.12	-6.07
Interest Expense	0.38	-0.01	-0.07	-	0.00	6.13
Interest & Investment Income	-	-	-	0.15	-0.09	0.10
Other Income / (Expense), net	0.04	-0.32	0.07	0.00	-0.03	-0.03
Income Tax Expense	-	-	-	0.00	-0.00	0.22
Preferred Stock Dividends Declared	-	-	-	-	0.51	1.26
Basic Earnings per Share	($2.10)	($1.92)	($1.11)	($7.05)	($12.52)	($7.13)
Weighted Average Basic Shares Outstanding	4.93M	8.33M	11.07M	751.07K	1.03M	4.98M
Diluted Earnings per Share	($2.10)	($1.92)	($1.11)	($7.05)	($12.52)	($7.13)
Weighted Average Diluted Shares Outstanding	4.93M	8.33M	11.07M	751.07K	1.03M	4.98M
Weighted Average Basic & Diluted Shares Outstanding	-	8.33M	18.33M	19.26M	1.91M	33.40M

This table shows Virios Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-1.24	-1.10	-1.29	-1.05	-2.28	-8.24	-12	-3.81	-16	-3.78	-4.99
Consolidated Net Income / (Loss)	-1.24	-1.10	-1.29	-1.05	-2.28	-7.73	-11	-3.81	-16	-3.78	-4.99
Net Income / (Loss) Continuing Operations	-1.24	-1.10	-1.29	-1.05	-2.28	-7.73	-11	-3.81	-16	-3.78	-4.99
Total Pre-Tax Income	-1.24	-1.10	-1.29	-1.05	-2.28	-7.73	-11	-3.81	-16	-3.75	-4.99
Total Operating Income	-1.27	-1.14	-1.31	-1.07	-2.30	-7.54	-4.43	-3.92	-16	-3.81	-5.08
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	1.27	1.14	1.31	1.07	2.30	7.54	4.43	3.92	16	3.81	5.08
Selling, General & Admin Expense	0.90	0.84	0.97	0.73	1.77	5.23	1.99	1.35	1.29	1.47	2.41
Research & Development Expense	0.37	0.30	0.34	0.34	0.54	2.32	2.44	2.57	15	2.34	2.67
Total Other Income / (Expense), net	0.04	0.03	0.02	0.02	0.02	-0.19	-6.30	0.12	0.06	0.06	0.07
Interest Expense	-	-	0.00	0.00	0.00	-	6.13	0.00	0.00	-	0.00
Interest & Investment Income	0.04	-	0.02	0.02	0.02	-0.16	-0.15	0.11	0.08	0.05	0.08
Other Income / (Expense), net	-	-	0.00	0.00	0.00	-0.03	-0.02	0.00	-0.02	0.01	-0.01
Income Tax Expense	-	-	0.00	0.00	0.00	-0.00	0.19	0.00	-0.00	0.03	0.00
Basic Earnings per Share	($1.62)	($1.47)	($1.68)	($1.15)	($2.05)	($8.02)	($8.45)	($1.99)	($8.20)	($0.76)	($0.15)
Weighted Average Basic Shares Outstanding	763.75K	751.07K	770.32K	916.03K	1.11M	1.03M	1.44M	1.91M	1.92M	4.98M	33.54M
Diluted Earnings per Share	($1.62)	($1.47)	($1.68)	($1.15)	($2.05)	($8.02)	($8.45)	($1.99)	($8.20)	($0.76)	($0.15)
Weighted Average Diluted Shares Outstanding	763.75K	751.07K	770.32K	916.03K	1.11M	1.03M	1.44M	1.91M	1.92M	4.98M	33.54M
Weighted Average Basic & Diluted Shares Outstanding	19.26M	19.26M	19.26M	27.76M	1.33M	1.91M	1.91M	1.91M	2.29M	33.40M	33.63M

This table details how cash moves in and out of Virios Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	29	-16	-6.98	-3.71	12	-8.33
Net Cash From Operating Activities	-3.90	-16	-11	-4.87	-8.79	-16
Net Cash From Continuing Operating Activities	-3.90	-16	-11	-4.87	-8.79	-16
Net Income / (Loss) Continuing Operations	-10	-16	-12	-5.30	-12	-34
Consolidated Net Income / (Loss)	-10	-16	-12	-5.30	-12	-34
Depreciation Expense	-	-	-	0.00	0.01	0.00
Amortization Expense	0.05	-	-	0.00	0.06	0.05
Non-Cash Adjustments To Reconcile Net Income	7.37	0.32	0.58	0.62	4.07	18
Changes in Operating Assets and Liabilities, net	-0.97	-0.05	0.20	-0.19	-0.58	0.09
Net Cash From Investing Activities	0.00	0.00	0.00	0.00	3.76	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00	0.00	3.76	0.00
Divestitures	-	-	-	0.00	3.76	0.00
Net Cash From Financing Activities	33	-0.10	4.49	1.16	17	7.28
Net Cash From Continuing Financing Activities	33	-0.10	4.49	1.16	17	7.28
Repurchase of Common Equity	-	-	0.00	-	0.00	-0.05
Issuance of Debt	1.99	-	-	0.00	15	3.00
Issuance of Common Equity	31	-0.30	4.49	0.00	1.38	4.25
Other Financing Activities, net	0.18	0.20	-	1.16	-0.00	0.09

This table details how cash moves in and out of Virios Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.20	-1.47	-0.94	0.64	-0.98	13	2.69	-4.15	-3.27	-3.60	6.70
Net Cash From Operating Activities	-0.96	-1.47	-0.94	-0.81	-0.91	-6.13	-4.68	-4.03	-3.27	-3.64	-4.59
Net Cash From Continuing Operating Activities	-0.96	-1.47	-0.94	-0.81	-0.91	-6.13	-4.68	-4.03	-3.27	-3.64	-4.63
Net Income / (Loss) Continuing Operations	-1.24	-1.10	-1.29	-1.05	-2.28	-7.73	-11	-3.81	-16	-3.78	-4.99
Consolidated Net Income / (Loss)	-1.24	-1.10	-1.29	-1.05	-2.28	-7.73	-11	-3.81	-16	-3.78	-4.99
Depreciation Expense	-	-	0.00	-	-	0.01	0.02	0.02	-0.03	-	0.00
Amortization Expense	-	-	0.00	-	-	0.06	0.05	-	-	-	0.00
Non-Cash Adjustments To Reconcile Net Income	0.15	0.15	0.14	0.15	0.09	3.69	6.23	0.06	12	0.07	0.47
Changes in Operating Assets and Liabilities, net	0.13	-0.51	0.21	0.09	1.28	-2.16	-0.05	-0.30	0.55	0.08	-0.11
Net Cash From Investing Activities	-	-	0.00	-	-	3.76	0.00	-	-	-	0.00
Net Cash From Continuing Investing Activities	-	-	0.00	-	-	3.76	0.00	-	-	-	0.00
Net Cash From Financing Activities	1.16	-	0.00	1.45	-0.07	15	7.37	-0.12	-	0.03	11
Net Cash From Continuing Financing Activities	1.16	-	0.00	1.45	-0.07	15	7.37	-0.12	-	0.03	11
Repurchase of Common Equity	-	-	-	-	-	-	0.00	-	-	-	-0.11
Issuance of Debt	-	-	0.00	-	-	15	3.00	-	-	-	0.00
Other Financing Activities, net	-	-	0.00	1.45	-0.07	-1.38	4.37	-0.12	-	-4.17	11
Effect of Exchange Rate Changes	-	-	0.00	-	-	-	0.00	0.01	-	-	-0.00

This table presents Virios Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	31	16	8.37	4.17	94	90
Total Current Assets	31	16	8.37	4.17	17	8.43
Cash & Equivalents	30	14	7.03	3.32	15	6.52
Prepaid Expenses	1.68	1.77	1.34	0.85	1.70	1.91
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.02	0.01
Total Noncurrent Assets	0.00	0.00	0.00	0.00	78	82
Goodwill	-	-	-	0.00	12	12
Intangible Assets	-	-	-	0.00	66	69
Other Noncurrent Operating Assets	-	-	-	0.00	0.22	0.18
Other Noncurrent Nonoperating Assets	-	-	-	-	0.00	0.16
Total Liabilities & Shareholders' Equity	31	16	8.37	4.17	94	90
Total Liabilities	1.53	1.28	1.04	0.36	30	15
Total Current Liabilities	1.53	1.28	1.04	0.36	3.18	3.06
Accounts Payable	0.37	0.35	0.57	0.11	1.23	0.76
Accrued Expenses	1.16	0.92	0.47	0.25	1.89	2.24
Current Deferred Revenue	-	-	-	-	-	0.00
Other Current Liabilities	-	-	-	0.00	0.05	0.06
Total Noncurrent Liabilities	0.00	0.00	0.00	0.00	27	12
Noncurrent Deferred Revenue	-	-	-	-	-	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	0.00	11	12
Other Noncurrent Operating Liabilities	-	-	-	0.00	16	0.11
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	0.00	74	0.00
Total Equity & Noncontrolling Interests	30	15	7.33	3.81	-10	75
Total Preferred & Common Equity	30	15	7.33	3.81	-10	75
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	30	15	7.33	3.81	-10	75
Common Stock	58	58	63	66	68	184
Retained Earnings	-28	-44	-56	-61	-74	-108
Treasury Stock	-	-	0.00	-0.30	-0.30	-0.30
Accumulated Other Comprehensive Income / (Loss)	-	-	-	0.00	-3.86	-0.59

This table presents Virios Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	5.25	3.22	3.64	2.28	97	97	92	95
Total Current Assets	5.25	3.22	3.64	2.28	19	15	12	15
Cash & Equivalents	4.79	2.38	3.02	2.04	18	13	10	13
Prepaid Expenses	0.46	0.85	0.62	0.24	1.62	1.30	1.53	1.78
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.01
Total Noncurrent Assets	0.00	0.00	0.00	0.00	78	82	80	80
Goodwill	-	-	-	-	12	12	12	12
Intangible Assets	-	-	-	-	66	69	68	68
Other Noncurrent Operating Assets	-	-	-	-	0.21	0.21	0.19	0.17
Other Noncurrent Nonoperating Assets	-	-	-	-	-	-	-	0.00
Total Liabilities & Shareholders' Equity	5.25	3.22	3.64	2.28	97	97	92	95
Total Liabilities	0.49	0.57	0.50	1.33	14	14	15	15
Total Current Liabilities	0.49	0.57	0.50	1.33	2.58	1.89	2.60	2.56
Accounts Payable	0.21	0.20	0.22	0.45	1.15	0.50	0.58	0.14
Accrued Expenses	0.28	0.37	0.28	0.88	1.38	1.33	1.96	2.35
Current Deferred Revenue	-	-	-	-	-	-	-	0.01
Other Current Liabilities	-	-	-	-	0.05	0.05	0.05	0.06
Total Noncurrent Liabilities	0.00	0.00	0.00	0.00	12	12	12	12
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	0.03
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	12	12	12	12
Other Noncurrent Operating Liabilities	-	-	-	-	0.14	0.13	0.12	0.09
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	76	76	70	0.00
Total Equity & Noncontrolling Interests	4.76	2.65	3.14	0.95	7.09	6.88	7.26	81
Total Preferred & Common Equity	4.76	2.65	3.14	0.95	7.09	6.88	7.26	81
Preferred Stock	0.00	0.00	0.00	0.00	25	25	40	0.00
Total Common Equity	4.76	2.65	3.14	0.95	-18	-18	-33	81
Common Stock	65	66	67	67	71	71	73	196
Retained Earnings	-60	-63	-64	-66	-85	-89	-104	-113
Treasury Stock	-0.30	-0.30	-0.30	-0.30	-0.30	-0.30	-0.30	-0.30
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	-3.80	-0.27	-1.64	-1.72

This table displays calculated financial ratios and metrics derived from Virios Therapeutics' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	8,330,390.00	18,330,390.00	19,257,937.00	1,332,178.00	2,293,162.00
DEI Adjusted Shares Outstanding	0.00	333,216.00	733,216.00	770,317.00	1,332,178.00	2,293,162.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-47.90	-16.70	-6.88	-9.66	-15.49
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-61.08%	23.26%	55.53%	-123.75%	-129.27%
EBIT Growth	0.00%	-60.21%	23.26%	55.53%	-125.05%	-128.39%
NOPAT Growth	0.00%	-56.33%	21.26%	55.77%	-124.48%	-128.74%
Net Income Growth	0.00%	-54.26%	23.26%	56.76%	-133.19%	-177.39%
EPS Growth	0.00%	8.57%	42.19%	56.76%	-77.59%	43.05%
Operating Cash Flow Growth	0.00%	-302.79%	26.91%	57.53%	-80.49%	-77.67%
Free Cash Flow Firm Growth	0.00%	0.00%	25.43%	52.43%	-1,334.94%	33.29%
Invested Capital Growth	0.00%	238.70%	-40.05%	65.80%	9,989.45%	37.99%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	9.36%	16.76%	14.87%	-109.29%	11.71%
EBIT Q/Q Growth	0.00%	9.36%	16.76%	14.87%	-110.50%	11.88%
NOPAT Q/Q Growth	0.00%	12.50%	14.56%	14.87%	-109.97%	11.78%
Net Income Q/Q Growth	0.00%	11.09%	16.76%	15.09%	-115.71%	10.33%
EPS Q/Q Growth	0.00%	28.09%	36.57%	15.09%	-142.64%	65.77%
Operating Cash Flow Q/Q Growth	0.00%	-22.60%	17.94%	19.80%	-112.93%	13.77%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	14.32%	20.14%	-1,810.23%	57.64%
Invested Capital Q/Q Growth	0.00%	261.14%	152.43%	2,111.61%	4,633.53%	1.42%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.65%
Interest Burden Percent	103.86%	100.00%	100.00%	97.23%	100.75%	121.57%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-34.56%	-71.83%	-112.22%	-95.14%	-36.28%	-49.23%
Cash Return on Invested Capital (CROIC)	0.00%	-3,538.84%	-2,136.87%	-1,020.38%	-230.36%	-65.21%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-34.56%	-71.83%	-112.22%	-95.14%	3.37%	-22.91%
Return on Equity Simple (ROE_SIMPLE)	-34.56%	-110.06%	-167.17%	-139.12%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.00	-11	-8.62	-3.81	-8.56	-20
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-11.22%	-22.88%	-34.48%	-28.67%	-41.74%	-136.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-100.16%	84.54%	-26.14%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-9.96	-16	-12	-5.45	-12	-28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.91	-16	-12	-5.45	-12	-28
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.75	2.94	0.59	2.91	0.00	0.13
Price to Tangible Book Value (P/TBV)	0.75	2.94	0.59	2.91	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	58.03	0.00	15.83	1.27	0.04
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.00	-0.99	-0.96	-0.93	-0.27	-0.15
Leverage Ratio	1.05	1.06	1.11	1.13	1.45	1.33
Compound Leverage Factor	1.09	1.06	1.11	1.09	1.46	1.61
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	115.75%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	-15.75%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.68	13.91	-10.69	-5.35	-1.29	-2.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	109.28%	53.46%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	20.55	12.37	8.02	11.62	5.21	2.76
Quick Ratio	19.45	10.98	6.74	9.25	4.67	2.13
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-11	-8.42	-4.01	-58	-38
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	-6.25
Operating Cash Flow to Interest Expense	-10.14	0.00	0.00	0.00	0.00	-2.55
Operating Cash Flow Less CapEx to Interest Expense	-10.14	0.00	0.00	0.00	0.00	-2.55
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.15	0.49	0.30	0.49	49	68
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	0.35	-0.20	0.19	49	19
Enterprise Value (EV)	-7.27	29	-2.71	7.76	63	3.01
Market Capitalization	23	43	4.33	11	3.32	9.54
Book Value per Share	$6.08	$1.74	$0.40	$0.20	($7.60)	$32.66
Tangible Book Value per Share	$6.08	$1.74	$0.40	$0.20	($65.79)	($2.83)
Total Capital	30	15	7.33	3.81	64	75
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-30	-14	-7.03	-3.32	-15	-6.52
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.15	0.49	0.30	0.49	-1.48	-1.15
Debt-free Net Working Capital (DFNWC)	30	15	7.33	3.81	13	5.37
Net Working Capital (NWC)	30	15	7.33	3.81	13	5.37
Net Nonoperating Expense (NNE)	3.34	5.01	3.63	1.48	3.79	15
Net Nonoperating Obligations (NNO)	-30	-14	-7.03	-3.32	-15	-6.68
Total Depreciation and Amortization (D&A)	0.05	0.00	0.00	0.00	0.07	0.05
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($1.92)	($1.11)	$0.00	($12.52)	($7.13)
Adjusted Weighted Average Basic Shares Outstanding	0.00	8.33M	11.07M	0.00	1.03M	4.98M
Adjusted Diluted Earnings per Share	$0.00	($1.92)	($1.11)	$0.00	($12.52)	($7.13)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	8.33M	11.07M	0.00	1.03M	4.98M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	8.33M	18.33M	0.00	1.91M	33.40M
Normalized Net Operating Profit after Tax (NOPAT)	-7.00	-11	-8.62	-3.81	-8.56	-20
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-25.93	0.00	0.00	0.00	0.00	-4.56
NOPAT to Interest Expense	-18.23	0.00	0.00	0.00	0.00	-3.19
EBIT Less CapEx to Interest Expense	-25.93	0.00	0.00	0.00	0.00	-4.56
NOPAT Less CapEx to Interest Expense	-18.23	0.00	0.00	0.00	0.00	-3.19
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	-0.72%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.72%	0.00%	0.00%	0.00%	0.00%	-0.16%

This table displays calculated financial ratios and metrics derived from Virios Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	19,247,437.00	19,257,937.00	38,515,874.00	19,257,937.00	27,757,937.00	1,332,178.00	1,911,128.00	1,911,128.00	1,911,128.00	2,293,162.00	33,401,553.00
DEI Adjusted Shares Outstanding	769,897.00	770,317.00	1,540,635.00	770,317.00	1,110,317.00	1,332,178.00	1,911,128.00	1,911,128.00	1,911,128.00	2,293,162.00	33,401,553.00
DEI Earnings Per Adjusted Shares Outstanding	-1.60	-1.43	-0.84	-1.36	-2.05	-6.19	-6.37	-1.99	-8.24	-1.65	-0.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	50.53%	44.33%	15.62%	27.58%	-80.58%	-559.18%	-233.60%	-264.67%	-589.16%	49.38%	-15.93%
EBIT Growth	50.53%	44.33%	15.62%	27.58%	-80.58%	-565.39%	-238.88%	-266.28%	-587.76%	49.85%	-14.13%
NOPAT Growth	50.84%	45.54%	15.62%	27.58%	-80.58%	-562.68%	-237.11%	-266.71%	-587.00%	49.53%	-14.59%
Net Income Growth	52.05%	46.04%	14.87%	27.14%	-84.66%	-600.51%	-746.02%	-262.66%	-590.35%	51.08%	54.36%
EPS Growth	52.05%	46.04%	14.87%	27.14%	-84.66%	-445.58%	-402.98%	-73.04%	-300.00%	90.52%	98.22%
Operating Cash Flow Growth	61.32%	45.00%	44.81%	-9.34%	5.24%	-317.34%	-399.52%	-395.98%	-259.59%	40.68%	2.04%
Free Cash Flow Firm Growth	8.08%	21.68%	41.60%	45.52%	61.94%	-5,370.77%	-6,125.22%	-8,201.65%	-14,477.25%	60.45%	91.56%
Invested Capital Growth	95.68%	65.80%	169.71%	0.00%	-4,376.88%	9,989.45%	23,613.05%	59,692.28%	6,268.30%	37.99%	3.35%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	13.74%	10.69%	-15.46%	18.59%	-115.10%	-226.02%	41.57%	11.01%	-306.50%	76.05%	-33.82%
EBIT Q/Q Growth	13.74%	10.69%	-15.46%	18.59%	-115.10%	-229.09%	41.20%	12.01%	-303.89%	76.00%	-33.82%
NOPAT Q/Q Growth	13.74%	10.69%	-15.46%	18.59%	-115.10%	-227.75%	41.26%	11.44%	-302.97%	75.92%	-33.37%
Net Income Q/Q Growth	14.28%	10.68%	-17.06%	18.70%	-117.24%	-238.84%	-41.37%	65.15%	-313.53%	75.99%	-31.91%
EPS Q/Q Growth	14.28%	10.68%	-17.06%	18.70%	-117.24%	-291.22%	-5.36%	76.45%	-312.06%	90.73%	80.26%
Operating Cash Flow Q/Q Growth	-29.37%	-52.97%	36.19%	13.41%	-12.12%	-573.69%	23.63%	14.02%	18.71%	-11.13%	-26.12%
Free Cash Flow Firm Q/Q Growth	9.80%	30.75%	-10.27%	20.90%	36.98%	-9,852.97%	-25.48%	-5.49%	-10.65%	73.00%	73.24%
Invested Capital Q/Q Growth	0.00%	2,111.61%	-43.87%	-57.95%	-1,043.00%	4,633.53%	31.92%	6.02%	-2.72%	1.42%	-1.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	99.99%	101.78%	100.00%	99.99%	100.85%	100.02%
Interest Burden Percent	96.92%	96.93%	98.27%	98.13%	99.11%	102.05%	241.05%	97.16%	99.49%	98.70%	98.10%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-89.19%	-95.14%	-138.04%	-149.22%	-200.48%	-36.28%	-51.48%	-57.75%	-97.54%	-49.23%	-34.67%
Cash Return on Invested Capital (CROIC)	0.00%	-1,020.38%	-2,024.46%	-6,007.21%	0.00%	-230.36%	-231.12%	-236.12%	-134.62%	-65.21%	-33.51%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-89.19%	-95.14%	-138.04%	-149.22%	-200.48%	3.37%	9.19%	10.10%	40.00%	-22.91%	-13.31%
Return on Equity Simple (ROE_SIMPLE)	-130.99%	0.00%	-191.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.89	-0.80	-0.92	-0.75	-1.61	-5.28	-3.10	-2.75	-11	-2.66	-3.55
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-4.71%	-5.92%	-10.66%	-19.93%	-19.63%	-26.96%	-78.56%	-12.92%	-76.90%	-10.37%	-9.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-20.93%	-34.65%	-23.88%	-169.66%	52.15%	-43.76%	-39.92%	-152.47%	-3.56%	-4.41%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-1.27	-1.14	-1.31	-1.07	-2.30	-7.57	-4.45	-3.92	-16	-3.80	-5.08
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.27	-1.14	-1.31	-1.07	-2.30	-7.50	-4.38	-3.90	-16	-3.80	-5.08
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.74	2.91	3.48	1.32	4.97	0.00	0.00	0.00	0.00	0.13	0.87
Price to Tangible Book Value (P/TBV)	3.74	2.91	3.48	1.32	4.97	0.00	0.00	0.00	0.00	0.00	117.93
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	15.83	24.90	9.69	0.00	1.27	1.42	1.39	1.71	0.04	0.85
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.04	-0.93	-0.95	-0.96	-1.20	-0.27	-0.23	-0.19	-0.16	-0.15	-0.19
Leverage Ratio	1.15	1.13	1.15	1.16	1.32	1.45	1.17	1.17	1.20	1.33	1.18
Compound Leverage Factor	1.12	1.09	1.13	1.14	1.31	1.48	2.83	1.14	1.20	1.31	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	30.21%	30.28%	52.12%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	115.75%	91.44%	91.67%	90.62%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	-15.75%	-21.64%	-21.95%	-42.74%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.11	-1.93	-17.89	-19.54	-41.23	-1.12	-0.77	-0.87	-1.43	-1.37	1.22
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	109.28%	117.86%	117.48%	141.01%	53.46%	61.61%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.77	11.62	5.66	7.27	1.71	5.21	7.43	7.80	4.49	2.76	5.86
Quick Ratio	9.82	9.25	4.17	6.04	1.53	4.67	6.80	7.11	3.90	2.13	5.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.43	-0.99	-1.09	-0.86	-0.54	-54	-68	-72	-79	-21	-5.74
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-11.09	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.76	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.76	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.02	0.49	0.27	0.12	-1.09	49	65	69	67	68	67
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.54	0.19	0.17	0.12	-1.07	49	65	69	68	19	2.19
Enterprise Value (EV)	13	7.76	6.85	1.12	2.68	63	93	96	115	3.01	57
Market Capitalization	18	11	9.23	4.14	4.72	3.32	9.57	9.12	15	9.54	70
Book Value per Share	$0.25	$0.20	$0.14	$0.16	$0.03	($7.60)	($13.44)	($9.48)	($17.31)	$32.66	$2.41
Tangible Book Value per Share	$0.25	$0.20	$0.14	$0.16	$0.03	($65.79)	($71.69)	($52.26)	($59.23)	($2.83)	$0.02
Total Capital	4.76	3.81	2.65	3.14	0.95	64	83	83	77	75	81
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-4.79	-3.32	-2.38	-3.02	-2.04	-15	-18	-13	-10	-6.52	-13
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.02	0.49	0.27	0.12	-1.09	-1.48	-0.96	-0.58	-1.07	-1.15	-0.78
Debt-free Net Working Capital (DFNWC)	4.76	3.81	2.65	3.14	0.95	13	17	13	9.06	5.37	12
Net Working Capital (NWC)	4.76	3.81	2.65	3.14	0.95	13	17	13	9.06	5.37	12
Net Nonoperating Expense (NNE)	0.34	0.31	0.37	0.30	0.67	2.45	7.82	1.06	4.68	1.12	1.43
Net Nonoperating Obligations (NNO)	-4.79	-3.32	-2.38	-3.02	-2.04	-15	-18	-13	-10	-6.68	-13
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.07	0.07	0.02	-0.03	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.50)	($36.75)	($1.75)	($1.25)	($2.05)	($8.02)	($8.45)	($1.99)	($8.20)	($0.76)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	763.75K	30.04K	770.32K	916.03K	1.11M	1.03M	1.44M	1.91M	1.92M	4.98M	33.54M
Adjusted Diluted Earnings per Share	($1.50)	($36.75)	($1.75)	($1.25)	($2.05)	($8.02)	($8.45)	($1.99)	($8.20)	($0.76)	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	763.75K	30.04K	770.32K	916.03K	1.11M	1.03M	1.44M	1.91M	1.92M	4.98M	33.54M
Adjusted Basic & Diluted Earnings per Share	$0.00	($36.75)	$0.00	$0.00	$0.00	($8.02)	$0.00	$0.00	$0.00	($0.76)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	770.32K	770.32K	770.32K	1.11M	1.33M	1.91M	1.91M	1.91M	2.29M	33.40M	33.63M
Normalized Net Operating Profit after Tax (NOPAT)	-0.89	-0.80	-0.92	-0.75	-1.61	-5.28	-3.10	-2.75	-11	-2.66	-3.55
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.73	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.51	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.73	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-0.51	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.16%	-0.57%

Financials Breakdown Chart

Virios Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Virios Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Virios Therapeutics' net income appears to be on an upward trend, with a most recent value of -$34.26 million in 2025, rising from -$10.35 million in 2020. The previous period was -$12.35 million in 2024.

Virios Therapeutics' total operating income in 2025 was -$27.97 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $27.97 million

Over the last 5 years, Virios Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Virios Therapeutics' total liabilities were at $15.27 million at the end of 2025, a 49.1% decrease from 2024, and a 897.1% increase since 2020.

In the past 5 years, Virios Therapeutics' cash and equivalents has ranged from $3.32 million in 2023 to $29.80 million in 2020, and is currently $6.52 million as of their latest financial filing in 2025.

Over the last 5 years, Virios Therapeutics' book value per share changed from 6.08 in 2020 to 32.66 in 2025, a change of 437.5%.

Related Companies

Financial statements for NASDAQ:VIRI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Financials

Financials Breakdown Chart

Virios Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Financials

Annual Income Statements for Virios Therapeutics

Quarterly Income Statements for Virios Therapeutics

Annual Cash Flow Statements for Virios Therapeutics

Quarterly Cash Flow Statements for Virios Therapeutics

Annual Balance Sheets for Virios Therapeutics

Quarterly Balance Sheets for Virios Therapeutics

Annual Metrics And Ratios for Virios Therapeutics

Quarterly Metrics And Ratios for Virios Therapeutics

Financials Breakdown Chart

Virios Therapeutics Financials - Frequently Asked Questions

When does Virios Therapeutics' fiscal year end?

How has Virios Therapeutics' net income changed over the last 5 years?

What is Virios Therapeutics' operating income?

How has Virios Therapeutics' revenue changed over the last 5 years?

How much debt does Virios Therapeutics have?

How much cash does Virios Therapeutics have?

How has Virios Therapeutics' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools